There are number of challenges in the elimination of the three blood-borne viruses — HIV, hepatitis B (HBV), and hepatitis C (HCV). Treatment advances have been made with the introduction of highly effective antiviral agents into clinical practice, and prevention strategies. However, for worldwide elimination of these viruses, effective vaccines are required. Dr Marina Klein (McGill University Health Centre, Montreal, Canada) joins touchINFECTIOUS DISEASES to discuss the global health burden of HIV, HBV and HCV, the challenges associated with the elimination of these viruses, and a look at future therapeutic developments.
The presentation entitled ‘Triple elimination: HIV, HCV, HBV’ was presented at the International AIDS Society (IAS) 29 July – 2 August, 2022.
Questions:
- Could you tell us a little about the global health burden of human immunodeficiency virus (HIV), hepatitis B (HBV) and hepatitis C (HCV)? (00:16)
- What are the challenges of elimination of HIV, HBV and HCV and how may they be overcome? (00:56)
- What therapeutic developments do you anticipate in the coming years? (02:34)
Disclosures: Marina Klein is a consultant for Gilead Science; receives grant/research support from Abbvie, Gilead Sciences, and ViiV Healthcare; and is on the advisory board for Abbvie, and ViiV Healthcare.
Support: Interview and filming supported by Touch Medical Media. Interview conducted by Shanice Allen.
